Stockreport

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for ...

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in t [Read more]